https://eupraxiapharma.com/publication/safety-and-pharmacokinetics-of-ep-104iar-sustained-release-fluticasone-propionate-in-knee-osteoarthritis-a-randomized-double-blind-placebo-controlled-phase-1-trial/ 2025-08-14T19:36:08+00:00 https://eupraxiapharma.com/publication/ep-104iar-long-acting-intra-articular-injection-of-fluticasone-propionate-results-from-a-phase-2-randomized-double-blind-vehicle-controlled-trial-in-318-subjects-with-knee-osteoarthritis/ 2025-08-23T20:43:16+00:00 https://eupraxiapharma.com/publication/results-from-dose-escalation-in-resolve-an-ongoing-phase-1b-2a-dose-escalation-study-of-ep-104gi-extended-release-fluticasone-propionate-intra-esophageal-injection-for-eosinophilic-esophagitis/ 2025-08-24T02:08:54+00:00 https://eupraxiapharma.com/publication/initial-results-from-resolve-a-phase-1b-2a-dose-escalation-study-of-ep-104gi-extended-release-fluticasone-propionate-intra-esophageal-injection-for-eosinophilic-esophagitis/ 2025-08-24T02:33:01+00:00 https://eupraxiapharma.com/publication/initial-results-from-resolve-an-ongoing-phase-1b-2a-dose-escalation-study-of-ep-104gi-long-acting-fluticasone-propionate-injectable-suspension-for-eosinophilic-esophagitis/ 2025-08-24T02:36:30+00:00 https://eupraxiapharma.com/publication/pharmacokinetic-profile-of-intra-articular-fluticasone-propionate-microparticles-in-beagle-dog-knees/ 2025-08-25T11:49:43+00:00 https://eupraxiapharma.com/publication/tackling-unmet-medical-need-how-slow-release-intra-articular-corticosteroids-could-play-a-role-in-improving-quality-of-life-and-reducing-risk-in-osteoarthritis/ 2025-09-05T03:51:00+00:00 https://eupraxiapharma.com/publication/efficacy-and-safety-of-a-diffusion-based-extended-release-fluticasone-propionate-intra-articular-injection-ep-104iar-in-knee-osteoarthritis-springboard-a-24-week-multicentre-randomised-double/ 2025-09-05T03:51:54+00:00 https://eupraxiapharma.com/publication/results-from-dose-escalation-cohorts-1-6-of-resolve-an-ongoing-phase-1b-2a-study-of-ep-104gi-long-acting-fluticasone-propionate-injectable-suspension-for-eosinophilic-esophagitis/ 2025-10-26T22:48:13+00:00 https://eupraxiapharma.com/publication/persistent-improvement-in-dysphagia-symptoms-for-52-weeks-following-a-single-administration-of-ep-104gi-in-resolve-an-ongoing-phase-1b-2-trial-in-eosinophilic-esophagitis/ 2025-10-29T17:18:24+00:00 https://eupraxiapharma.com/publication/updated-results-from-resolve-ongoing-study-of-ep-104gi-long-acting-fluticasone-propionate-injection-for-eosinophilic-esophagitis/ 2025-11-24T20:18:04+00:00 https://eupraxiapharma.com/publication/updated-dose-escalation-results-from-resolve-an-ongoing-phase-1b-2a-study-of-ep-104gi-long-acting-fluticasone-propionate-injectable-suspension-for-eosinophilic-esophagitis/ 2025-11-24T20:19:45+00:00 https://eupraxiapharma.com/publication/results-from-resolve-an-ongoing-phase-1b-2a-study-of-ep-104gi-long-acting-fluticasone-propionate-injectable-suspension-for-eosinophilic-esophagitis-dose-escalation-cohorts-3-through-6/ 2025-11-24T20:21:14+00:00 https://eupraxiapharma.com/publication/pharmacokinetics-and-local-tolerability-of-ep-104gi-an-extended-release-formulation-of-fluticasone-for-treatment-of-eosinophilic-esophagitis-after-intra-esophageal-injection-in-mini-pigs/ 2025-11-24T20:23:27+00:00 https://eupraxiapharma.com/publication/efficacy-and-pharmacokinetic-results-from-ongoing-dose-escalation-in-resolve-a-phase-1b-2a-study-of-ep-104gi-extended-release-fluticasone-propionate-intra-esophageal-injection-for-eosinophilic-esop/ 2025-11-24T20:23:59+00:00 https://eupraxiapharma.com/publication/ep-104iar-extended-release-intra-articular-injection-of-fluticasone-propionate-shows-sustained-pain-response-for-subjects-with-moderate-baseline-pain-and-bmi-less-than-30-in-springboard-a-phase-2/ 2025-11-24T20:24:22+00:00 https://eupraxiapharma.com/publication/ep-104iar-long-acting-intra-articular-injection-of-fluticasone-propionate-shows-sustained-improvement-in-pain-for-subjects-with-moderate-baseline-pain-and-bmi-less-than-30-in-springboard-a-phase-2/ 2025-11-24T20:24:44+00:00 https://eupraxiapharma.com/publication/results-from-dose-escalation-from-resolve-an-ongoing-phase-1b-2a-study-of-ep-104gi-long-acting-fluticasone-propionate-injectable-suspension-for-eosinophilic-esophagitis/ 2025-11-24T20:26:41+00:00 https://eupraxiapharma.com/publication/prevalence-and-causes-of-severe-esophageal-strictures-requiring-multiple-dilations-in-the-united-states/ 2025-11-24T20:27:16+00:00 https://eupraxiapharma.com/publication/kol-event-with-guest-dr-evan-dellon-to-discuss-data-from-the-resolve-trial/ 2025-12-03T00:20:59+00:00 https://eupraxiapharma.com/publication/single-administration-of-ep-104gi-in-resolve-a-phase-1b-2-trial-in-eosinophilic-esophagitis-improves-endoscopic-features-of-inflammation-and-fibrosis-over-36-weeks/ 2026-05-05T11:17:02+00:00 https://eupraxiapharma.com/publication/durability-of-dysphagia-improvements-following-single-administration-of-ep-104gi-in-participants-with-eosinophilic-esophagitis-during-dose-escalation-in-the-resolve-trial/ 2026-05-05T11:18:57+00:00 https://eupraxiapharma.com/publication/resolve-a-phase-1b-2-study-evaluating-the-safety-efficacy-and-pharmacokinetics-of-ep-104gi-in-adults-with-eosinophilic-esophagitis/ 2026-05-05T11:19:23+00:00 https://eupraxiapharma.com/publication/single-administration-of-escalating-doses-of-ep-104gi-leads-to-persistent-improvements-in-histological-features-of-eosinophilic-esophagitis-over-36-weeks-in-resolve-a-phase-1b-2-dose-escalation-and-o/ 2026-05-05T11:20:46+00:00 https://eupraxiapharma.com/publication/improvements-in-dysphagia-following-single-administration-of-ep-104gi-persist-over-52-weeks-during-dose-escalation-in-the-ongoing-resolve-phase-1b-2-trial-in-eosinophilic-esophagitis/ 2026-10-12T20:07:33+00:00 https://eupraxiapharma.com/publication/single-administration-of-escalating-doses-of-ep-104gi-leads-to-improvements-in-frequency-and-severity-of-dysphagia-up-to-52-weeks-in-the-resolve-phase-1b-2-study-in-eosinophilic-esophagitis/ 2026-10-18T14:30:07+00:00 https://eupraxiapharma.com/publication/improvements-in-histopathological-features-of-eosinophilic-esophagitis-following-a-single-administration-of-ep-104gi-during-dose-escalation-in-the-phase-1b-2-resolve-study/ 2026-10-19T14:22:59+00:00